None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: a. Age >= 19 b. hemoptysis amount =< 200cc/24hr c. Stable vital sign - heart rate < 100 beats/min - Systolic blood pressure > 90 mmHg - Respiratory rate < 24 breaths/min - SpO2 > 90% d. No history of intervention or surgery within 3 years to control hemoptysis e. bronchial artery hypertrophy on CT f. Benign lung parenchymal disease (e.g., tuberculosis, bronchiectasis) on CT
Exclusion criteria
Exclusion criteria: a. Patients with anticoagulation / antiplatelet agents b. Coagulopathy (INR>1.5) or thrombocytopenia (Platelet count <50K) c. Pregnant or lactating women d. Malignant neoplasms in the lung and bronchus e. Traumatic hemoptysis f. Iatrogenic hemoptysis g. Pulmonary artery thromboembolism h. Vasculitis i. Contraindication to tranexamic acid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-month hemoptysis-free rate | — |
Secondary
| Measure | Time frame |
|---|---|
| hemoptysis of cessation after treatment;duration;Serious adverse event | — |
Countries
Korea, Republic of
Contacts
Seoul National University Hospital